Related Experiment Video
Updated: Jan 21, 2026

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
Published on: September 13, 2024
PERK/eIF-2α/CHOP Pathway Dependent ROS Generation Mediates Butein-induced Non-small-cell Lung Cancer Apoptosis and
Shouyin Di1, Chongxi Fan2, Zhiqiang Ma1
1Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, 1 Xinsi Road, Xi'an 710038, China.
Abstract:
Butein, a member of the chalcone family, is a potent anticarcinogen against multiple cancers, but its specific anti-NSCLC mechanism remains unknown. The present study examined the effects of butein treatment on NSCLC cell lines and NSCLC xenografts. Butein markedly decreased NSCLC cell viability; inhibited cell adhesion, migration, invasion, and colony forming ability; and induced cell apoptosis and G2/M phase arrest in NSCLC cells. Moreover, butein significantly inhibited PC-9 xenograft growth. Both in vivo and in vitro studies verified that butein exerted anti-NSCLC effect through activating endoplasmic reticulum (ER) stress-dependent reactive oxygen species (ROS) generation. These pro-apoptotic effects were reversed by the use of 4- phenylbutyric acid (4-PBA), CHOP siRNA, N-acetyl-L-cysteine (NAC) and Z-VAD-FMK (z-VAD) in vitro. Moreover, inhibition of ER stress markedly reduced ROS generation. In addition, in vivo studies further confirmed that inhibition of ER stress or oxidative stress partially abolished the butein-induced inhibition of tumor growth. Therefore, butein is a potential therapeutic agent for NSCLC, and its anticarcinogenic action might be mediated by ER stress-dependent ROS generation and the apoptosis pathway.
Insights
Butein effectively combats non-small cell lung cancer (NSCLC) by inducing apoptosis via endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) generation. This study highlights butein as a potential therapeutic agent for NSCLC treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Butein, a chalcone, shows anticancer properties but its mechanism against non-small cell lung cancer (NSCLC) is unclear.
- Understanding butein's anti-NSCLC effects is crucial for developing novel cancer therapies.
Purpose of the Study:
- To investigate the anti-NSCLC effects of butein.
- To elucidate the underlying molecular mechanisms, focusing on endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) generation.
Main Methods:
- Treated NSCLC cell lines and PC-9 xenografts with butein.
- Assessed cell viability, adhesion, migration, invasion, colony formation, apoptosis, and cell cycle.
- Utilized 4-phenylbutyric acid (4-PBA), CHOP siRNA, N-acetyl-L-cysteine (NAC), and Z-VAD-FMK (z-VAD) to investigate mechanisms.
- Measured ER stress and ROS generation both in vitro and in vivo.
Main Results:
- Butein significantly reduced NSCLC cell viability, migration, invasion, and colony formation, while inducing apoptosis and G2/M phase arrest.
- Butein inhibited PC-9 xenograft growth in vivo.
- The anti-NSCLC effects were mediated by activating ER stress-dependent ROS generation, which was reversed by inhibiting ER stress or oxidative stress.
Conclusions:
- Butein exhibits potent anti-NSCLC activity through ER stress-dependent ROS generation and apoptosis induction.
- Butein is a promising therapeutic candidate for NSCLC treatment.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
cAMP-dependent Protein Kinase Pathways
Generation of Three-Phase Voltage
As the rotor...
Apoptosis
Lung Capacity
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...

